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ObjectivOs: Evaluar el impacto sobre el presupuesto anual de salud de Chile por la 
inclusión de Daclatasvir/Asunaprevir (DCV/ASV) para el tratamiento de la Hepatitis 
C genotipo 1b. MetOdOlOgíAs: Se modeló la cohorte de pacientes Chilenos con 
Hepatitis C genotipo 1b utilizando datos de prevalencia e incidencia locales de acu-
erdo a la metodología sugerida por la guía de buenas prácticas ISPOR. Se comparó el 
escenario en el que todos los pacientes reciben Peginterferon/Ribavirina (PR) versus 
el escenario donde todos los pacientes son tratados con DCV/ASV. El análisis fue 
realizado desde la perspectiva del sistema de salud público Chileno asumiendo 100% 
de cobertura de los fármacos. Se introdujeron costos asociados al tratamiento farma-
cológico, de eventos adversos, recursos relevantes (monitoreo mediante exámenes 
de laboratorio, anatomía patológica, imágenes y controles médicos) y costos asocia-
dos a complicaciones de la enfermedad. Se consideró un horizonte de tiempo de 5 
años. ResultAdOs: El impacto sobre el presupuesto anual (tomando como base el 
de 2015) se presenta para tres precios posibles de DCV/ASV. A CL$1.500.000 pesos 
chilenos (CL$) semanales se requieren CL$42.928.668.276 adicionales el primer año 
(tratamiento de casos prevalentes) lo que equivale a un 0.71% del presupuesto anual. 
Desde el año 2 en adelante (asumiendo tratar sólo casos incidentes) el monto asciende 
a CL$8.031.019.832 adicionales (0,13% del presupuesto nacional 2015). A CL$1.000.000 
semanal, se requieren CL$25.015.902.617 adicionales el primer año y CL$4.679.931.106 
adicionales desde el año 2 (0,11% y 0,6% del presupuesto anual de salud 2015). A 
CL$500.000 semanales se requieren CL$ 7.103.136.957 adicionales el primer año y 
CL$1.328.842.381 adicionales a partir del segundo año (0,3% y al 0,057% del presu-
puesto nacional 2015 respectivamente). cOnclusiOnes: En los rangos de precios 
estudiados, el impacto sobre el presupuesto de salud chileno oscila entre el 0,3% y 
0,71% para el primer año, el cual disminuiría a menos del 0,15% desde el segundo año.
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Inflammatory bowel disease (IBD) is associated with high costs, high morbidity and 
decreased quality of life in patients. In Mexico and Brazil, there is no concise data 
about prevalence of Crohn´s Disease (CD) estimated to range from 0.0008% to 1.11% 
and no cost data attributable to IBD.Objectives: To assess the average annual cost per 
patient with CD treated with biologics from the perspective of the government health-
care system both in Mexico and Brazil. MethOds: Biologic treatments examined 
included certolizumab pegol (CZP) 400 mg weeks 0, 2, 4 and then every 4 weeks; adali-
mumab (ADA) 160 mg week 0, 80 mg week 2 and then 40 mg every 2 weeks; infliximab 
(INF) 5 mg / kg at weeks 0, 2, 6, and every 8 weeks thereafter. Medication acquisition 
costs were assessed for CZP and ADA, while costs for INF assessed both acquisition 
and administration (infusion). Average weight per patient in the analyses was 70kg. 
Prices were obtained from the Mexican Social Security Institute (IMSS) and ANVISA 
for Brazil. Exchange rates were obtained from public sources (1USD= 0.0675MXN; 
1USD= 2.7BRL). Results: The analysis for Mexico shows lower costs in the first year 
of treatment (induction and maintenance) with CZP (USD$7,719/year) vs ADA and INF 
(USD$12,792, USD$17,313/year, respectively), leading to cost savings per patient/year 
compared with CZP of approximately USD$5,073 and USD$9,594 versus adalimumab 
and infliximab. In Brazil, similar Resultswere seen: CZP (USD$7,186/year) versus ADA 
(USD$24,813/year) and INF (USD$31,004/year), showing savings with CZP of USD$17,627 
vs ADA and USD$23,818 vs INF per year. The savings are even greater with CZP in the 
maintenance years. cOnclusiOns: Certolizumab pegol shows savings when com-
pared to adalimumab and infliximab in the first year of treatment and maintenance, 
which can lead to an important impact on institutional budgets.
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Objectives: Comparing efficacy and costs of treatment strategies using terli-
pressin or noradrenaline for cirrhotic patients with hepatorenal syndrome, under 
the perspectives of Brazilian public health system, a major general hospital and a 
major private health insurance. MethOds: Comparison of efficacy was performed 
through a systematic review with meta-analysis of randomized controlled trials, 
using random-effects model. Economic evaluation was performed through cost-
minimization. Results: Four studies (154 patients) were included in the meta-
analysis. There was no evidence of difference between treatments with terlipressin 
or noradrenaline regarding 30-day survival (risk ratio of 1.04, 95% confidence inter-
val of 0.84-1.30, p= 0.70). Under the perspective of the public health system, costs of 
treatments with terlipressin or noradrenaline were 287.77 and 2,960.45 International 
Dollars (Int$) respectively. Under the perspective of the general hospital, costs of 
the treatments with terlipressin or noradrenaline were Int$7,437.04 and Int$8,406.41 
respectively. Regarding the perspective of the private health insurance, costs of treat-
ments with terlipressin and noradrenaline were Int$13,484.57 and Int$15,061.01 
respectively. cOnclusiOns: There was no evidence of superiority between treat-
ment strategies using terlipressin or noradrenaline regarding survival of patients 
with hepatorenal syndrome, but the strategy using terlipressin was more economical 
under three different perspectives.
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demographics. Results: The total number of CAM users were 148, out of which 
87 (58.8%) were females and 61 (41.2%) were males. Most of the participants (n= 51, 
34.5%) were uneducated and belongs to large families (n= 89, 60.1%). Most of par-
ticipants use CAM to lower their glycemic level, majority (n= 125, 84.5%) of which 
belief that CAM can lower their sugar level. However, only 12% of the participants 
disclose this CAM use to their physician. cOnclusiOns: The finding of current 
study indicates that most of diabetic CAM users population belief that CAM can con-
trol their glycemic level. However, the rate of CAM disclosure to physician was very 
low. Efforts should be made to encourage their diabetic CAM user to disclose their 
CAM use to their physician so he will give them better advise for gycemic control.
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Objectives: The study aims were to investigate patient’s preferences in clinical 
outcomes and patient burden to administer insulin injections, as measured by 
patients’ willingness to pay (WTP). MethOds: Existing national email panels in 
Argentina, Brazil, Chile, Colombia and Mexico were used to collect survey-based 
data from adults > 18 years with type 2 diabetes (T2DM) treated with insulin injec-
tions. Resultswere analysed using a standard choice model designed for discrete 
choice experiment (DCE). Clinical outcomes related to efficacy (reduction in HbA1c) 
and safety (severe (SH) and non-severe hypoglycaemic (NSH) events and change in 
weight) and the patient burden of insulin administration (preparation of insulin 
prior to injecting and number of daily injections) were found to be relevant fac-
tors in qualitative research in patients and were examined in the DCE. Results: 
A total of 1537 people (54% males) with T2DM completed the survey. Participants 
placed high monetary value on efficacy and safety outcomes; they would pay 74 
USD/month to reduce HbA1c by 1% and 80 USD/month to reduce one SH event per 
year. To reduce one NSH per week participants were willing to pay 91 USD/month. 
Participants wanting to lose weight reported a WTP of 37 USD/month to lose 3 kg. 
To avoid preparation of insulin prior to injection, participants reported a WTP of 18 
USD/month and the WTP/month for one fewer injection/day was 25 USD. Potential 
limitations of this study are that preferences expressed may not match preferences 
in real-life situations, and bias through recruiting via internet panels since these 
may not be representative of typical patients. cOnclusiOns: Clinical outcomes 
and administrative burden were significant predictors of choice in people with 
T2DM. Reducing HbA1c as well as number of SH and NSH were the highest valued 
outcomes. In addition, the administrative burden of insulin injections was also 
considered important.
dIAbetes/endoCrIne dIsorders – health Care use & Policy studies
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Objectives: Patient education is a key component for the management of acute 
and chronic conditions. However, majority of such educational sessions are reported 
from the healthcare settings. The present study therefore, aims to evaluate whether 
a home-based intervention can result in better understanding about Diabetes 
Mellitus Type 2 and can increase medication adherence to the prescribed thera-
pies. MethOds: A non-clinical randomized control trial was conducted whereby 
participants received a home-based educational intervention through a registered 
pharmacist. Diabetes knowledge and medication adherence were measured by 
means of self-administered questionnaires. Descriptive statistics were used to 
describe the demographic and disease characteristics of the patients. Inferential 
statistics were used for inter- and intra- group comparisons. SPSS 18 was used 
for data analysis. P< 0.05 was taken as significant. Results: One hundred and 
fifty patients were randomly assigned to two groups (75 patients in each arm). No 
significant differences were observed in either group for demographic variables. 
There was, however, a significant increase in the participants’ levels of knowledge 
about Diabetes Mellitus type 2 and medication adherence among the Home-based 
intervention group at the completion of the intervention (p< 0.001). Significantly 
lower HbA1c levels were also observed among the Home-based intervention group 
after completion of the intervention (p< 0.001). cOnclusiOns: Pharmacist-led 
home-based intervention can significantly increase disease-related knowledge 
and medication adherence in patients with type 2 diabetes mellitus. This study 
hereby concludes that home-based interventional programs should be utilized as 
a compelling method of patient education and counselling.
GAstroIntestInAl dIsorders – Cost studies
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Objectives: Determine whether adalimumab reduces costs for the public health 
sector in the treatment of moderate to severe active ulcerative colitis in adult 
patients who have had an inadequate response to conventional therapy in com-
parison with infliximab. MethOds: Adalimumab was considered comparable 
with infliximab in the treatment of Ulcerative Colitis through a systematic review 
of the literature. A cost minimization analysis was then considered appropriate 
under the perspective of the public health care system in Mexico and a time 
horizon of five years. Direct drug and administration costs were considered. 
Univariate and multivariate probabilistic sensitivity analyses were performed. 
Finally, we assessed the budget impact of potential savings. Results: The model 
Resultsshowed that the cost with adalimumab treatment for five years (using an 
annual discount rate of 5%) is $ 96,365.87 (11.2%) lower than the total cost with 
infliximab. This generates savings to the health system. Resultshave a high sensi-
tivity to patient weight, but expected costs in all simulated populations are lower 
with adalimumab. In the base case, the present value of the 5-year budget impact 
with a discount rate of 5% represents savings around $ 348,748,074.14 pesos if 
adalimumab is used in 100% of estimated prevalence in Mexico. cOnclusiOns: 
Adalimumab proved to be an alternative that minimizes expected costs under 
the investigated scenarios given the evidence of comparable efficacy versus inf-
liximab. Also, savings allow greater access to care for patients with UC, benefiting 
the health institution, not only by improving the quality of care with an innova-
tive therapy but also by allowing significant savings that could be used to treat a 
larger number of patients.
GAstroIntestInAl dIsorders – Patient-reported outcomes & Patient  
Preference studies
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Objectives: The Study Was Conducted to evaluate the use of complementary 
and alternative medicine in Hepatitis-C patients In Quetta, Pakistan MethOds: 
A cross sectional study was conducted from March to September, 2014. Hepatitis-C 
patients having confirm diagnosis visiting different facilities in Quetta city for 
the treatment of their disease, were included in the study. The data was collected 
by use of pre-validated tool made specifically for this study. The descriptive sta-
tistics was used to present the demographic and disease related information. All 
analyses were performed using SPSS 20.0. Results: A total of 389 patients were 
registered in different health facilities of the study out of which 284 patients 
agree to participate in the study. One hundred and seventy two (60.5 %) were 
using complementary and alternative medicine for the treatment of their disease 
along with conventional therapy, Herbal treatment was majorly practiced (41.9 
%) complementary and alternative method, followed by religious Methods(35.0 
%). One hundred and thirty two (76.7 %) of these consult a complementary and 
alternative medicine practitioner. Majority (N= 154, 90%) of the respondents were 
satisfied with the Complementary and Alternative Medicine Methodsthey used 
for treatment of Hepatitis C. cOnclusiOns: The findings of the study show that 
the use of Complementary & Alternative Medicine is prevalent in Hepatitis-C 
patients in Quetta, Pakistan. People satisfied with the use of Complementary 
& Alternative Medicine methods. Further research is needed to evaluate the 
reasons and outcomes for Complementary & Alternative Medicine use by 
patients.
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ObjetivOs: Verificar se há diferença na qualidade de vida entre pacientes por-
tadores da hepatite C que estão em tratamento (com interferon peguilado mais 
ribavirina associado ou não a um inibidor de protease) com aqueles que não estão 
em tratamento. MétOdOs: Estudo observacional, transversal mediante a apli-
cação de 3 questionários auto-administráveis sendo dois genéricos: Short Form 36 
Questionnaire (SF-36) e Euroqol 5D (EQ-5D) e um específico para doenças hepáti-
cas: Chronic Liver Disease Questionnaire (CLDQ). Os questionários foram aplicados 
em pacientes com hepatite C após a aprovação pelo Comitê de Ética do Hospital de 
Clínicas da Universidade Federal do Paraná e da Secretaria Municipal de Saúde de 
Curitiba, Paraná. Os pacientes assinaram o termo de consentimento livre esclare-
cido (TCLE). Os dados coletados foram tabelados no programa Microsoft Excel 2013 
e a análise estatística feita pelo programa Minitab® 17. ResultAdOs: Através da 
prova de Mann-Whitney (IC 95%), obteve-se diferença estatisticamente signifi-
cante (p< 0,05) no SF-36 nos domínios aspectos físicos e aspectos emocionais assim 
como no CLDQ nos domínios: fadiga, sintomas sistêmicos, atividades, função 
emocional. Não houve tal diferença (p< 0,05) no EQ-5D, porém o valor utility médio 
para pacientes em tratamento foi de 0,661 e para os não tratados 0,733 assim 
como o valor médio da escala analógica visual (VAS) sendo respectivamente 0,57 
e 0,73. cOnclusões: A administração de questionários genéricos com o suporte 
de um questionário específico, que é sensível a aspectos peculiares da doença, 
evidencia que o tratamento tem uma influência negativa na qualidade de vida dos 
pacientes com hepatite C denotando um maior cuidado no manejo dos mesmos 
pela equipe de saúde.
Objectives: To estimate the direct costs of HCV management for genotype 1 
patients throughout their lifetime based on the natural history of the disease from 
payer perspective in Colombia MethOds: Direct costs were estimated from a 
payer perspective by using a micro-costing approach of all relevant resources used 
to manage patients with HCV genotype 1 since the diagnosis for a lifetime perspec-
tive. Resources and clinical practice were identified, measured and valued for nine 
health states. Resource use and clinical patterns were validated with a panel of 
experts in managing HCV patients by applying a comprehensive survey. Each of the 
resources was valued based on standard national public lists of fees in Colombian 
pesos. Total costs for each of the health states of the disease were calculated for 
a one year time horizon Results: Direct cost were presented in US Dollars using 
the average year to date exchange rate (USD 1 = COP 1,974). Estimated average 
direct cost for each health state per year non diagnostic HCV (USD 512), chronic 
HCV F0-F3 (USD 1,440), compensated cirrhosis (USD 976), decompensated cirrhosis 
(USD 10,782), hepatocellular carcinoma (USD 10,263), liver transplantation (USD 
28,883), post-transplant (USD 1,933), monitoring drug therapy for HCV and the 
management of adverse events (USD 1,020), death (USD 15,538). cOnclusiOns: 
Chronic HCV infection represents an important economic and humanistic bur-
den for health systems in the world. This micro-costing study provides valuable 
information for further economic cost of illness analysis from the Colombian 
payers setting. It also reflects severity and economic impact of HCV related health 
states.
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Objectives: To estimate the impact on costs resulting from expanded biologics 
use in treating Crohn’s disease (CD) in Latin America over 10 years. MethOds: The 
influence of increasing biologics use for CD therapy during 2013–2023 was mod-
eled from a societal perspective. The model incorporated current and projected 
changes in medical (inpatient and outpatient services), indirect (productivity loss), 
and drug costs; population size; gross domestic product; and CD prevalence. Costs 
associated with expanded biologics use (estimated annual rate of increase 7.41%, 
21.07%, and 4.97% in Brazil, Colombia, and Mexico, respectively) were compared 
with non-expanded use (no increase from 2013 levels). The expanded-use sce-
nario incorporated additional drug costs and benefits (medical and indirect cost 
reduction) attributed to expanded biologics use. Average annual per-patient costs 
of CD therapy and cost offsets based on biologics use were aggregated with base 
annual medical and indirect costs to estimate total cost per patient. Total per-
country annual costs were estimated using population size and CD prevalence. 
Costs were adjusted to currency year 2013. Sensitivity analyses of model inputs 
(CD prevalence and growth of prevalence) assessed model robustness. Results: 
Expanded biologics use was associated with slower annual cost growth vs. non-
expanded use; projected per-patient 2023 costs were R$19,689 vs. R$22,235 in 
Brazil, COP$15.70 million vs. COP$18.66 million in Colombia, and MXN$76,353 
vs. MXN$82,170 in Mexico. Differences were driven by greater medical and indi-
rect cost offsets with expanded vs. non-expanded use (e.g., R$4,390 vs. R$2,148 
[medical] and R$6,723 vs. R$3,290 [indirect]). Expanded biologics use resulted in 
10-year cumulative net cost savings of R$0.08 billion in Brazil, COP$503 billion in 
Colombia, and MXN$1.8 billion in Mexico. cOnclusiOns: Increasing biologics 
use to treat CD may limit cost growth over time by reducing medical and indirect 
costs. These findings may inform policy decisions regarding biologics use for CD 
in Latin America.
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ObjetivOs: O objetivo desse estudo foi realizar uma revisão sistemática sobre 
custo-efetividade do tenofovir para o tratamento de pacientes com hepatite B 
crônica. MétOdOs: Foi realizada uma extensiva busca sistemática na literatura 
por meio das bases de dados Pubmed, Scopus, ScienceDirect, Cochrane, Scielo, HTA 
e ISPOR, além da busca manual, de artigos publicados até fevereiro de 2015. As 
estratégias utilizadas foram “cost-effectiveness” OR “cost-utility” AND “hepatitis 
B treatment” AND “tenofovir”. Os estudos incluídos foram referentes a avaliações 
econômicas do tipo custo-efetividade e custo-utilidade em pacientes adultos e 
portadores de Hepatite B crônica. A intervenção utilizada foi o uso de tenofovir 
em comparação às outras alternativas para o tratamento da doença (lamivudina, 
telbivudina, adefovir, entecavir, interferon alfa e interferon alfa peguilado) e/ou 
nenhum tratamento. Os desfechos avaliados foram os custos relacionados com 
as melhorias de saúde (RCEI, AVAQ e AVG). ResultAdOs: Ao total, 1185 artigos 
foram encontrados e apenas 15 atendiam aos critérios de inclusão. O tenofovir foi a 
estratégia mais custo-efetiva em 2/3 dos artigos selecionados. Nos demais estudos, 
o fator limitante para o tenofovir ser classificado como a melhor estratégia, foi 
o seu custo, pois é possível observar que houveram melhorias nos desfechos em 
saúde avaliados, sendo em alguns casos tão efetivo quanto as alternativas domi-
nantes. cOnclusões: Resultados relevantes foram encontrados, sugerindo que 
o tenefovir é o medicamento mais custo-efetivo para o tratamento da hepatite B 
crônica e também como terapia de resgate. O seu baixo risco de desenvolvimento 
de resistência, aliado ao efeito de proporcionar melhorias na saúde em anos de 
vida ganhos e anos de vida ajustados pela qualidade, além de diminuir as taxas 
de incidência de cirrose, hepatocarcinoma celular e transplantes hepáticos refor-
çam esse resultado. Os desfechos demonstrados podem contribuir na tomada de 
decisão do clínico, na busca pela melhor alternativa para o paciente.
